Xtant Medical Holdings, Inc. - FORM 8-K - EX-99.1

Attached files

file	filename
8-K - Xtant Medical Holdings, Inc.	v189893_8k.htm
EX-99.2 - Xtant Medical Holdings, Inc.	v189893_ex99-2.htm
EX-10.4 - Xtant Medical Holdings, Inc.	v189893_ex10-4.htm
EX-10.2 - Xtant Medical Holdings, Inc.	v189893_ex10-2.htm
EX-21.1 - Xtant Medical Holdings, Inc.	v189893_ex21-1.htm
EX-10.8 - Xtant Medical Holdings, Inc.	v189893_ex10-8.htm
EX-3.2(A) - Xtant Medical Holdings, Inc.	v189893_ex3-2a.htm
EX-10.7 - Xtant Medical Holdings, Inc.	v189893_ex10-7.htm
EX-10.6 - Xtant Medical Holdings, Inc.	v189893_ex10-6.htm
EX-10.5 - Xtant Medical Holdings, Inc.	v189893_ex10-5.htm
EX-10.9 - Xtant Medical Holdings, Inc.	v189893_ex10-9.htm
EX-99.3 - Xtant Medical Holdings, Inc.	v189893_ex99-3.htm
EX-10.3 - Xtant Medical Holdings, Inc.	v189893_ex10-3.htm
EX-10.10 - Xtant Medical Holdings, Inc.	v189893_ex10-10.htm

Exhibit 99.1

BACTERIN INTERNATIONAL, INC.

DECEMBER 31, 2009 AND 2008

Salt Lake Office:

5296 South Commerce Drive, Suite 300

Salt Lake City, Utah 84107-5370

Telephone: (801)281-4700

Kaysville Office:

1284 Flint Meadow Drive, Suite D

Kaysville, Utah 84037-9590

Telephone: (801)927-1337

Bacterin International, Inc.

Financial Statements

December 31, 2009 and 2008

Contents

		Page
Balance Sheets		4
Statements of Operations		5
Statement of Changes in Stockholders' Equity		6
Statements of Cash Flows		7
Notes to Financial Statements		8

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To The Board of Directors and Stockholders of

Bacterin International, Inc.

600 Cruiser Lane

Belgrade, MT 59714

We have audited the accompanying balance sheets of Bacterin International, Inc. (the Company) as of December 31, 2009 and 2008, and the related statements of operations, changes in stockholders’ equity and cash flows for the years ended December 31, 2009 and 2008. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States of America). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Bacterin International, Inc. as of December 31, 2009 and 2008, and the results of its operations and its cash flows for the years ended December 31, 2009 and 2008, in conformity with accounting principles generally accepted in the United States of America.

Child, Van Wagoner & Bradshaw, PLLC

Salt Lake City, Utah

June 18, 2010

BACTERIN INTERNATIONAL, INC.

Balance Sheets

As of December 31, 2009 and 2008

	December 31,
	2009			2008
ASSETS
Current Assets:
Cash and cash equivalents	$	54,155		$	238,895
Restricted cash and cash equivalents		-			1,000,000
Accounts receivable, net of allowance of $81,803 and $92,881, respectively		1,314,418			564,134
Notes receivable-trade		270,565			189,387
Notes receivable from stockholder		-			138,280
Inventories, net		5,000,713			4,158,690
Prepaid and other current assets		30,000			61,267
		6,669,851			6,350,653

Property & equipment, net		3,248,096			3,802,139
Intangible assets, net		554,268			548,772
Other assets		13,675			26,490

	$	10,485,890		$	10,728,054

LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable	$	1,403,950		$	1,253,601
Accrued liabilities		463,633			253,538
Warrants derivative liability		75,231			-
Notes payable		1,126,690			1,000,000
Notes payable to stockholders		183,461			154,032
Current portion of capital lease obligations		85,071			190,989
Current portion of convertible notes payable ($890,000 net of debt discount of $69,213)		820,787			-
Current portion of long-term debt		1,202,574			1,286,571
		5,361,397			4,138,731

Capital lease obligation, less current portion		27,074			62,673
Convertible notes payable, less current portion		-			2,340,000
Long-term debt, less current portion		412,545			563,878
		5,801,016			7,105,282
Stockholders' Equity
Preferred stock, $.0001 par value; 15,000,000 shares authorized; No shares issued and outstanding		-			-
Common stock, $.00001 par value; 85,000,000 shares authorized; 56,540,919 shares issued and 56,423,125 shares outstanding in 2009 and 50,718,134 shares issued and outstanding in 2008		565			507
Additional paid-in capital		22,238,210			16,973,858
Treasury stock, 117,794 shares		(76,566	)		-
Retained deficit		(17,477,335	)		(13,351,593	)
		4,684,874			3,622,772

	$	10,485,890		$	10,728,054

See Accompanying Notes to Financial Statements.

BACTERIN INTERNATIONAL, INC.

Statements of Operations

For the Years Ended December 31, 2009 and 2008

	December 31,
	2009			2008
REVENUE:
Product sales	$	7,101,357		$	8,031,611
Royalties and other		292,136			180,848
TOTAL REVENUE		7,393,493			8,212,459

Cost of product sales		2,318,142			1,522,658
GROSS PROFIT		5,075,351			6,689,801

OPERATING EXPENSES:
Selling, general, and administrative		4,161,941			3,417,904
Compensation expense		4,535,964			2,157,450
TOTAL OPERATING EXPENSES		8,697,905			5,575,354

INCOME (LOSS) FROM OPERATIONS		(3,622,554	)		1,114,447

INTEREST AND OTHER INCOME (EXPENSE)
Interest expense		(513,934	)		(1,374,360	)
Other		10,746			20,601
TOTAL INTEREST AND OTHER INCOME (EXPENSE), NET		(503,188	)		(1,353,759	)

NET INCOME (LOSS) BEFORE BENEFIT (PROVISION) FOR INCOME TAXES		(4,125,742	)		(239,312	)

BENEFIT (PROVISION) FOR INCOME TAXES		-			-

NET INCOME (LOSS)	$	(4,125,742	)	$	(239,312	)

Net income (loss) per share:
Basic	$	(.08	)	$	(.00	)
Shares used in the computation:
Basic		52,911,010			49,428,393

See Accompanying Notes to Financial Statements.

BACTERIN INTERNATIONAL, INC.

Statements of Changes in Stockholders’ Equity

For the Years Ended December 31, 2009 and 2008

																Total
	Common Stock					APIC Options/		Additional		Retained			Treasury			stockholders'
	Shares			Amount		Warrants		paid-in capital		Deficit			Stock			equity
Balance at December 31, 2007		48,154,701		$	481	$	2,220,747	$	12,074,104	$	(13,112,281	)	$	-		$	1,183,051
Issuance of common stock, options and warrants:
Private placement		2,283,433			23		348,117		930,374		-			-			1,278,514
Warrants issued on convertible debt		-			-		368,787		-		-			-			368,787
Stock based compensation		300,000			3		235,974		224,997		-			-			460,974
Warrants for debt/equity issuance		-			-		279,198		-		-			-			279,198
Warrants for short-term note guarantee		-			-		291,560		-		-			-			291,560
Net income		-			-		-		-		(239,312	)		-			(239,312	)
Balance at December 31, 2008		50,738,134			507		3,744,383		13,229,475		(13,351,593	)		-			3,622,772

Issuance of common stock, options and warrants:
Private placement		2,437,500			24		13,601		1,936,375		-			-			1,950,000
Conversion of notes to common stock		3,020,285			30		-		2,414,847		-			-			2,414,877
Purchase of treasury stock		(117,794	)		-		-		-		-			(76,566	)		(76,566	)
Warrants for debt issuance		-			-		62,183		-		-			-			62,183
Stock-based compensation		345,000			4		561,355		275,991		-			-			837,350
Net loss		-			-		-		-		(4,125,742	)		-			(4,125,742	)

Balance at December 31, 2009		56,423,125		$	565	$	4,381,522	$	17,856,688	$	(17,477,335	)	$	(76,566	)	$	4,684,874

See Accompanying Notes to Financial Statements.

BACTERIN INTERNATIONAL, INC.

Statements of Cash Flows

For the Years Ended December 31, 2009 and 2008

	Year Ended December 31,
	2009			2008
Operating activities:
Net income (loss)	$	(4,125,742	)	$	(239,312	)
Noncash adjustments:
Depreciation and amortization		707,926			685,715
Stock/option awards for services		837,350			460,974
Provision for losses on accounts receivable and inventory		(2,078	)		94,171
Non-cash interest expense		183,078			939,545
(Gain) Loss on disposal of assets		(5,250	)		1,051
Changes in operating assets and liabilities:
Accounts receivable		(739,206	)		346,984
Notes receivable-trade		(81,178	)		(68,344	)
Inventories		(851,023	)		(2,259,125	)
Prepaid and other current assets		44,082			(1,385	)
Accounts payable		150,349			582,756
Accrued liabilities		210,096			(41,022	)
Net cash provided by (used in) operating activities		(3,671,596	)		502,008

Investing activities:
Purchases of property and equipment		(42,089	)		(649,507	)
Note receivable from stockholder		138,280			(138,280	)
Intangible asset additions		(51,576	)		(167,905	)
Proceeds on sale of fixed assets		5,250			2,400
Acquisition of entity under common control		-			1,158
Net cash used by investing activities		49,865			(952,134	)

Financing activities:
Restricted cash		-			(1,000,000	)
Release of restriction on cash		1,000,000			-
(Payments on) long-term debt		(235,330	)		(2,018,536	)
Proceeds from issuance of convertible debt		550,000			2,340,000
(Payments on) notes payable		(500,000	)		-
Proceeds from notes payable		926,690			1,000,000
(Payments on) capital leases		(207,232	)		(216,092	)
Proceeds from issuance of common stock		1,950,000			1,278,514
Payments on notes payable to shareholders		(47,137	)		(838,717	)
Net cash provided by financing activities		3,436,991			545,169

Increase (decrease) in cash		(184,740	)		95,043

Cash and cash equivalents at beginning of period		238,895			143,852
Cash and cash equivalents at end of period	$	54,155		$	238,895

Supplemental disclosure of cash flow information (see note 19)

See Accompanying Notes to Financial Statements.

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements

Years ended December 31, 2009 and 2008

(1)	Business Description and Summary of Significant Accounting Policies

Business Description

Bacterin International, Inc. (“the “Company” or “Bacterin”) develops, manufactures and markets biologics products to domestic and international markets and is a leader in the field of biomaterials research, device development and commercialization. Bacterin’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and cartilage regeneration in knee and other joint surgeries.

Bacterin’s device division develops anti-microbial coatings to inhibit infection based upon proprietary knowledge of the phenotypical changes made by microbes as they sense and adapt to changes in their environment. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin’s strategic coating initiatives include the inhibition of biofilm formation, local (as opposed to systemic) drug delivery, local (as opposed to systemic) pain management, and anti-thrombotic factors for medical device applications.

Certain Risks and Concentrations

The Company's revenue is derived principally from the sale or license of its medical products, coatings and device implants. The markets in which the Company competes are highly competitive and rapidly changing. Significant technological advances, changes in customer requirements, or the emergence of competitive products with new capabilities or technologies could adversely affect the Company's operating results. The Company's business could be harmed by a decline in demand for, or in the prices of, its products or as a result of, among other factors, any change in pricing or distribution model, increased price competition, changes in government regulations or a failure by the Company to keep up with technological change. Further, a decline in available tissue donors could have an adverse impact on the business.

Financial instruments subjecting the Company to concentrations of credit risk are accounts and notes receivable. The Company maintains cash, cash equivalents, and short-term investments with various domestic financial institutions. From time to time, the Company's cash balances with its financial institutions may exceed insurance limits.

The Company's customers are worldwide with approximately 91% of sales in the United States in 2009 and 2008. One customer accounted for 12% of revenue in 2009. One customer accounted for 37% and another customer accounted for 10.2% of the Company's revenue in 2008. No single customer represented more than 10% of accounts receivable at December 31, 2009 and one customer represented 10.4% of accounts receivable at December 31, 2008.

Revenue by geographical region is as follows:

	Year Ended December 31,
	2009		2008
United States	$	6,708,027	$	7,485,988
Rest of World		685,466		726,471
	$	7,393,493	$	8,212,459

Use of Estimates

The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period; the carrying amount of property and equipment and intangible assets; valuation allowances for receivables and deferred income tax assets; and estimates of expected term and volatility in determining stock-based compensation expense. Actual results could differ from those estimates.

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(1)	Business Description and Summary of Significant Accounting Policies (Continued)

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents. Cash equivalents are recorded at cost, which approximates market value. As of December 31, 2008, a $1,000,000 certificate of deposit was pledged as collateral for the two $500,000 notes payable to Flathead Bank. The certificate of deposit was released as collateral during 2009.

Accounts Receivable and Notes Receivable

Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days and some customers are offered discounts for quick pay. Notes receivable include amounts due from West Coast Tissue Service, a supplier of donors to the Company. The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.

The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer's current creditworthiness, customer concentration, age of accounts receivable balance and general economic conditions that may affect a customer's ability to pay. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined using the specific identification method and includes materials, labor and overhead.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years for computers and equipment, and 30 years for buildings. Repairs and maintenance are expensed as incurred.

Intangible Assets

Intangible assets include costs to acquire and protect Company patents and are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives of 15 years.

Grants

As part of the Company’s efforts to build the development of new technologies, tissue donation and expansion of tissue supply, the Company, may, from time-to-time either provide or receive grants. These grants receipts are used for research and development efforts.

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(1)	Business Description and Summary of Significant Accounting Policies (Continued)

Revenue Recognition

Revenue is recognized when all of the following criteria are met: a) the Company has entered into a legally binding agreement with the customer; b) the products or services have been delivered; c) the Company's fee for providing the products and services is fixed and determinable; and d) collection of the Company’s fee is probable.

The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. If an arrangement includes a right of acceptance or a right to cancel, revenue is recognized when acceptance is received or the right to cancel has expired.

The Company sells to certain customers under consignment arrangements whereby the Company ships product to be stored by the customer. The customer is required to report the use to the Company and upon such notice the Company invoices the customer.

Research and development services revenue is recognized as performed, based on the incurrence of qualifying costs or achievement of milestones as prescribed in the arrangement.

Research and Development

Research and development costs, which are principally related to internal costs for the development of new technologies and processes for tissue and coatings, are expensed as incurred.

Income Taxes

The Company records income taxes under the asset and liability method as prescribed under FASB Accounting Standards Codification ASC 740, Accounting for Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When applicable, a valuation allowance is established to reduce any deferred tax asset when it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized.

Impairment of Long-Lived Assets

Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments of long-lived assets have been identified in any of the periods presented.

Net Income (Loss) Per Share

A reconciliation of the denominator used in the calculation of basic and diluted net income (loss) per share is as follows:

Net Income (Loss) Per Share:	Year Ended December 31,
	2009 (restated)			2008
Net Income (Loss)		(4,125,742	)	$	(239,312	)
Weighted average common shares outstanding for basic net income (loss) per share		52,911,010			49,428,393

Dilutive earnings per share are not reported as their effects are anti-dilutive.

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(1)	Business Description and Summary of Significant Accounting Policies (Continued)

Stock-Based Compensation

On January 1, 2006, the Company adopted the provisions of ASC 718-40, for its stock-based compensation plans. Under ASC 718, stock-based compensation costs are recognized based on the estimated fair value at the grant date for all stock-based awards. The Company estimates grant date fair values using the Black-Scholes-Merton option pricing model, which requires assumptions of the life of the award and the stock price volatility over the term of the award. The Company records compensation cost of stock-based awards using the straight line method, which is recorded into earnings over the vesting period of the award. Pursuant to the income tax provisions included in ASC 718-740, the Company has elected the “short cut method” of computing its hypothetical pool of additional paid-in capital that is available to absorb future tax benefit shortfalls.

Comprehensive Income (Loss)

Comprehensive loss includes net income or loss, as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. The Company currently does not have any transactions that qualify for accounting and inclusion as other comprehensive income (loss).

Fair Value of Financial Instruments

The carrying values of financial instruments, including accounts receivable, notes receivable, accounts payable and other accrued expenses, approximate their fair values.

(2)	Notes Receivable

Notes receivable consist of the following:

	Year Ended December 31,
	2009		2008

West Coast Tissue Service, Inc.	$	270,565	$	189,387

West Coast Tissue Service, Inc. is a non-profit corporation organized under Section 501(c)(3) of the Internal Revenue Code. The Company has contracted with West Coast Tissue Service to acquire their donor tissue for use in the Company’s production. If the Company were unable to continue to receive donor tissue, it may have a material effect on Bacterin’s financial statements and results of operations. The notes are non-interest bearing and are expected to be repaid during 2010.

(3)	Inventories

Inventories consist of the following:

	December 31,
	2009		2008
Raw materials	$	178,754	$	145,186
Raw materials		1,100,252		1,291,179
Work in process		1,282,080		735,916
Finished goods		2,499,627		2,037,409
		5,060,713		4,209,690
Reserve		60,000		51,000
	$	5,000,713	$	4,158,690

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(4)	Property and Equipment, Net

Property and equipment, net are as follows:

	December 31,
	2009			2008
Buildings	$	1,613,628		$	1,590,475
Equipment		2,542,855			2,553,053
Computer equipment		235,566			202,035
Computer software		140,071			127,867
Furniture and fixtures		75,007			75,007
Leasehold improvements		898,248			881,938
Vehicles		101,110			101,110
Total cost		5,606,485			5,551,485
Less: accumulated depreciation		(2,358,389	)		(1,729,346	)
	$	3,248,096		$	3,802,139

Maintenance and repairs expense for the years ended December 31, 2009 and 2008, was $43,328 and $67,863, respectively. Depreciation expense related to property, plant and equipment, including property under capital lease, for the years ended December 31, 2009 and 2008 was $661,847 and $508,392, respectively. Depreciation included in inventory and cost of goods sold for the years ended December 31, 2009 and 2008 was $192,500 and $251,076, respectively.

(5)	Intangible assets

Bacterin has been issued various patents with regards to processes for their products.

The following table sets forth information regarding intangible assets:

	Intellectual
	Property
As of December 31, 2008:
Gross carrying value	$	658,895
Accumulated amortization		(110,123	)
Net carrying value	$	548,772
As of December 31, 2009:
Gross carrying value	$	710,471
Accumulated amortization		(156,203	)
Net carrying value	$	554,268

Aggregate amortization expense:
2008	$	38,889
2009	$	46,080
Estimated amortization expense:
2010	$	47,364
2011	$	47,364
2012	$	47,364
2013	$	47,364
2014	$	47,364

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(6)	Accrued Liabilities

Accrued liabilities consist of the following:

	December 31,
	2009		2008
Credit cards	$	10,764	$	16,182
Accrued interest payable		45,382		112,536
Wages payable		377,484		40,439
Other accrued expenses		-		84,381
	$	463,630	$	253,538

(7)	Notes Payable

Notes payable consist of the following:

	December 31,
	2009		2008
Note payable Kevin Daly	$	200,000	$	-
Note payable Hamilton Group		426,693		-
Notes payable Flathead Bank		500,000		1,000,000

	$	1,126,693	$	1,000,000

The note payable to Kevin Daly was a 30-day note payable bearing interest at 15% and was repaid in January 2009. The notes payable Flathead Bank are 6.5% short-term notes with monthly payments of $3,728 and maturing on June 25, 2010. The notes payable Hamilton Group is a note due under a factoring contract, secured by accounts receivable.

(8)	Convertible Notes Payable

	December 31,
	2009 (restated)		2008

12% convertible note payable, maturing in 2010, extendable by the Company for two additional three month terms, secured by intellectual property and the raw material inventory, convertible into the securities offered in a future qualified offering, defined as the sale of debt or equity securities generating aggregate gross proceeds of at least $7,000,000, equal to the lower of $0.80 per share or ninety percent (90%) of the per share price of the securities sold to investors in the Qualified Financing if one occurs or convertible anytime into common stock at $1.00 per share, restrictive covenants were in compliance as of December 31, 2009 (net of debt discount). The debt discount is the value of the warrants that were issued.	$	480,787	$	-

10% convertible notes payable, maturing in 2010, secured by all assets after subordination to other creditors with pre-existing rights to those assets, convertible into shares of common stock – notes were repaid in January and February 2010		340,000		2,340,000
	$	820,787	$	2,340,000

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(9)	Long-Term Debt

Long-term debt consists of the following:

	December 31,
	2009			2008

6.5% loan payable to Flathead Bank, $7,278 monthly payments including interest, maturing June 25, 2010, secured by building	$	976,218		$	993,996

8.50% loan payable to Flathead Bank, $9,329 monthly payments, including interest, maturing in 2012, secured by equipment		293,052			367,376

5.00% loan payable to the City of Belgrade, $3,653 monthly payments, including interest, maturing in 2012, secured by equipment		141,215			149,158

5.00% loan payable to the City of Belgrade, $6,982 monthly payments, including interest, maturing in 2010, secured by equipment		39,044			118,557

5.00% loan payable to Valley Bank of Belgrade, $4,140 monthly payments including interest, secured by building		165,590			187,303

8.00% loan payable to Valley Bank of Belgrade, $4,140 monthly payments including interest, secured by building		-			34,059
		1,615,119			1,850,449

Less: Current portion		(1,202,574	)		(1,286,571	)
	$	412,545		$	563,878

The following is a summary of maturities due on the long-term debt as of December 31, 2009:

2010	$	1,202,574
2011		190,238
2012		180,029
2013		42,278
Thereafter		-

Total	$	1,615,119

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(10)	Capital Leasing Transactions

Future minimum capital and operating lease payments are as follows:

	December 31,
	2009			2008
2009	$	-		$	212,019
2010		93,752			39,519
2011		28,920			30,055
2012		-			-
Thereafter		-			-
Total minimum lease payments		122,672			281,593
Less interest portion of payments		(10,527	)		(27,931	)
Present value of future minimum lease payments		112,145			253,662
Less current maturities of capital lease obligation		(85,071	)		(190,989	)
Capital lease obligation	$	27,074		$	62,673

(11)	Notes Payable to Shareholders

Notes payable to shareholders consist of the following:

	December 31,
	2009		2008
Note payable shareholders	$	76,969	$	-
Note payable Mitch Godfrey		106,492		154,032
	$	183,461	$	154,032

During 2009, the Company repurchased stock from two shareholders pursuant to a tender process. These notes were given in payment for the stock and accrued interest at six percent during the initial term with a maturity of September 29, 2009. When the notes were not paid on the initial maturity date, they were automatically extended for an additional four months with a new interest rate of eight percent. If not paid at the second maturity date, these notes will automatically extend for an additional four months at an interest rate of ten percent. The note payable to Mitch Godfrey does not have specified payment terms and bears 6% interest per annum.

(12)	Related Party Transaction – ReGenCell, Inc.

ReGenCell, Inc. is a Montana corporation owned 100% by Guy Cook. On January 1, 2008, Bacterin International, Inc. acquired all of the assets of ReGenCell, Inc.:

Cash	$	1,158
Employee receivable – Guy Cook		32,700
Employee receivable – Mitchell Godfrey		17,763
Employee receivable – other		31,267
Fixed assets (at cost)		88,975
Accounts receivable – Bacterin International, Inc.		30,000
Notes receivable – Bacterin International, Inc.		59,055
Total assets purchased	$	260,918
Bacterin assumed Valley Bank note payable		(327,466	)
Bacterin assumed miscellaneous payables		(2,200	)
Bacterin reduced its payable to Guy Cook		68,748
	$	0

Guy Cook agreed to reduce his note receivable from Bacterin by the difference between the liabilities assumed and the assets purchased ($68,748). Upon acquisition of the employee receivables, Bacterin reduced its notes payable to Guy Cook and Mitchell Godfrey by $32,700 and $17,763, respectively.

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(13)	Stock-Based Compensation

The Company’s 2004 Stock Incentive Plan provides for stock awards, including options and performance stock awards, to be granted to employees, consultants, independent contractors, officers and directors. Awards are granted at the discretion of the Company’s board of directors, at an exercise price and term determined by the board. However, exercise prices are not less than the fair market value at the date of grant, and the term of the options is not greater than ten years. Options generally vest annually over a period of five years. At December 31, 2009, the Company had approximately 12 million shares available for issuance under the equity plan.

Compensation expense recognized in the statement of operations for the year ended December 31, 2009 and 2008 is based on awards ultimately expected to vest and reflects an estimate of awards that will be forfeited. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Compensation expense recognized and capitalized for the years ended December 31, 2009 and 2008 was $597,355 and $235,974 respectively.

The estimated fair value of stock options granted is done using the Black-Sholes method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:

Risk Free Rate: The risk-free rate is determined by reference to U.S. Treasury yields at or near the time of grant for time periods similar to the expected term of the award.

Expected Term: The Company does not have adequate history to estimate an expected term of stock-based awards, and accordingly, uses the short-cut method as prescribed by Staff Accounting Bulletin 107 to determine an expected term.

Volatility: Since the Company’s stock is not publicly-traded, the Company estimates expected volatility based on peer-companies as prescribed by ASC 718.

Dividend Yield: The dividend yield assumption is based on the Company’s history and expectation of dividend payouts and was 0% as of December 31, 2009 and 2008.

Activity under the Company’s stock option plans was as follows:

	2009					2008
				Weighted					Weighted
				Average					Average
				Exercise					Exercise
	Shares			Price		Shares			Price
Outstanding at Jan. 1,		3,998,326		$	0.59		3,414,744		$	0.55
Granted		2,995,000			0.76		1,384,083			0.75
Exercised					0.05
Cancelled or expired		(286,334	)		0.59		(800,501	)		0.87
Outstanding at December 31,		6,706,992		$	0.67		3,998,326		$	0.59
Exercisable at December 31,		3,006,901		$	0.56		1,939,911		$	0.44

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(14)	Stock-Based Compensation (continued)

The following table summarizes information concerning non-vested option transactions for the year ended December 31, 2009:

				Weighted
				Average
				Grant Date
				Fair Value
Nonvested Options	Shares			Per Share
Nonvested at January 1, 2009		2,058,415		$	0.61
Granted		2,995,000			0.76
Vested		(1,172,138	)		0.73
Forfeited		(181,186	)		0.77
Nonvested at December 31, 2009		3,700,091		$	0.75

From time to time the Company may grant stock options to consultants. The Company accounts for consultant stock options in accordance with ASC 505-50. Compensation expense for the grant of stock options to consultants is determined based on the estimated fair value of the warrants at the measurement date as defined in ASC 505-50 and is recognized over the vesting period.

In connection with private placements of convertible debt, short-term debt, and common stock, the Company issued warrants to purchase shares of common stock at an exercise price of between $0.5565 and $1.25 per share. During 2009, 80,000 warrants were issued with private placements of common stock, 180,000 warrants were issued with the placement of short-term debt and 220,000 warrants were issued with the placement of convertible notes. In 2008, 1,390,607, 100,000 and 976,288 warrants were issued in connection with convertible debt, short-term debt and common stock, respectively. The warrants were exercisable five to seven years from the date of grant. Warrants issued with common stock were recorded as additional paid in capital at the estimated fair market value of $13,601 in 2009 and $348,117 in 2008. The warrants issued with convertible debt and short-term loans were recorded as interest expense over the term of the debt at the estimated fair value of $62,183 in 2009 and $939,545 in 2008 using the following assumptions:

	2009			2008
Value of underlying common stock (per share)	$	.80		$	0.75
Risk free rate		2.20	%		1.87	%
Expected term	2.5-5 years			5-7 years
Dividend yield		0	%		0	%
Volatility		44-61	%		86	%

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(15)	Commitments and Contingencies

Operating Leases

The Company leases office facilities under a non-cancelable operating lease agreement with an expiration date in 2013. The Company has the option to extend the lease for another ten year term and has right of first refusal on any sale. The Company leases additional office facilities under month-to-month arrangements. Future minimum payments for the next five years and thereafter as of December 31, 2009, under these leases, are as follows:

2010	$	120,000
2011	$	120,000
2012	$	120,000
2013	$	72,258
Thereafter	$	-

Rent expense was $162,766 and $124,200 in 2009 and 2008, respectively. Rent expense is determined using the straight-line method of the minimum expected rent paid over the term of the agreement. The Company has no contingent rent agreements.

Warranties and Indemnification

The Company's arrangements generally include certain provisions for indemnifying customers against liabilities if its products or services infringe a third-party's intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications and has not accrued any liabilities related to such obligations in the accompanying financial statements.

The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person's service as a director or officer, including any action by the Company, arising out of that person's services as the Company's director or officer or that person's services provided to any other company or enterprise at the Company's request.

Litigation

From time to time, the Company is involved in legal proceedings arising in the ordinary course of business. The Company believes that the resolution of these matters will not have a material effect on the Company's financial position, results of operations or liquidity. Legal fees are charged to expense as incurred, unless the probability of incurring a loss is high and the amount can be reasonably estimated, in which case the estimated loss is accrued.

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(16)	Income Taxes

The components of income (loss) before provision for income taxes consist of the following:

	Year Ended December 31,
	2009 (restated)			2008
United States	$	(4,125,742	)	$	(239,312	)
	$	(4,125,742	)	$	(239,312	)

The components of the income tax provision are as follows:

	Year Ended December 31,
	2009		2008
Current:
Federal	$	-	$	-
State		-		-
Total current		-		-
Deferred:
Federal		-		-
State		-		-
Total deferred		-		-
	$	-	$	-

The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of 35% to income tax expense is as follows:

	Year Ended December 31,
	2009			2008
Statutory Federal tax rate	$	(1,444,010	)	$	(83,759	)
Valuation allowance		1,733,385			94,532
State income taxes, net of Federal benefit		(289,452	)		(16,513	)
Nondeductible meals & entertainment expense		24,301			5,740
Other		-			-
	$	-		$	-

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(17)	Income Taxes (continued)

Deferred tax components are as follows:

	At December 31,
	2009			2008
Deferred tax assets:
Accrued liability for vacation	$	85,734		$	35,355
Accrued commission expense		48,318			-
Bad debt reserve		34,275			38,917
Inventory reserve		25,140			21,369
Net operating loss carryovers		3,654,421			2,401,066
Stock warrant expense		843,321			843,321
Debt issuance expense		817,461			766,977
Stock compensation		661,296			411,005
Total deferred tax assets		6,169,966			4,518,010
Valuation allowance		(6,028,262	)		(4,324,140	)
Net deferred tax assets		141,704			193,870
Deferred tax liabilities:
Depreciation		(179,774	)		(232,478	)
Amortization		38,070			38,608
Total deferred tax liabilities		(141,704	)		(193,870	)
Net deferred tax assets	$	-		$	-

The ultimate realization of deferred tax assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence, management does not believe it is more likely than not that all of the deferred tax assets will be realized. Accordingly, the Company has established a valuation allowance equal to the net realizable deferred tax assets. The valuation allowance increased by $1,704,122 and $93,399 in 2009 and 2008, respectively.

At December 31, 2009 and 2008, the Company had total domestic Federal and state net operating loss carryovers of approximately $8,652,555 and $5,758,769, respectively. Federal net operating loss carryovers expire at various dates between 2027 and 2029, while state net operating loss carryovers expire between 2024 and 2029.

Under the Tax Reform Act of 1986, as amended, the amounts of and benefits from net operating loss carryovers and research and development credits may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three year period. The Company does not believe that such an ownership change has occurred in 2009 or 2008.

The 2006 through 2008 tax years remain open to examination by the Internal Revenue Service and the 2004 to 2008 tax years remain open to the Montana Department of Revenue. These taxing authorities have the authority to examine those tax years until the applicable statute of limitations expire.

BACTERIN INTERNATIONAL, INC.

Notes to Financial Statements (continued)

Years ended December 31, 2009 and 2008

(18)	Employee Benefit Plans

The Company has a SIMPLE IRA retirement plan established for qualified employees. Qualified employees may defer their salary and the deferrals are matched up to 3% of eligible compensation by the Company. The plan covers substantially all full-time employees. Under the terms of the plan, participants may contribute up to the lower of $10,500 of their salary or the statutorily prescribed limit to the plan. Employees are eligible the first January after their hire date. The Company made matching contributions during 2009 and 2008 of $131,709 and $46,993, respectively.

(19)	Supplemental Disclosure of Cash Flow Information

Supplemental cash flow information is as follows:

	Year Ended December 31,
	2009		2008
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest	$	276,074	$	308,881
Income taxes		-		-
Non-cash investing and financing activities:
Acquisition of receivables/equipment with assumed debt (see note 12)	$	-	$	259,760
Acquisition of property and equipment under capital lease	$	65,715	$	-
Acquisition of treasury stock using notes payable	$	76,566	$	-
Conversion of convertible notes payable into common stock	$	2,000,000	$	-

(20)	Subsequent Events

In January and February 2010, the Company issued an additional $2,450,000 of convertible notes on the same terms as the $550,000 of convertible notes issued in December 2009. The Company also renegotiated the convertible note agreements issued in December 2009 to include additional warrants as incentives for entering into these agreements so that all note agreements issued have the same terms and incentives.

In January and February 2010, the Company repaid all $340,000 of the 2008 convertible notes payable that were outstanding as of December 31, 2009.

Xtant Medical Holdings, Inc. - FORM 8-K - EX-99.1 - July 7, 2010

Attached files

Xtant Medical Holdings, Inc. Reports